Xenon Pharmaceuticals Inc. - Common Shares (XENE) earnings
XENE earnings moved a median of -1.64% by the close. Quarterly and annual XENE reports and results, each read against the price at its own news timestamp. Back to the XENE overview →
19 measured XENE earnings events.
Where these XENE earnings landedvs 17 measured XENE earnings reactions
| Middle 50% of XENE earnings reactions | -5.75% to +0.39% |
|---|---|
| Median reaction (to close) | -1.64% |
| Measured reactions | 17 |
Point-in-time · zero look-ahead
Half of the 17 XENE earnings events with a measured close landed between -5.75% and +0.39%; 35% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Xenon Pharmaceuticals For: Jun 30 | SEC filing · Form 10-Q | +1.00% | +0.57% | |
| Form 10-Q Xenon Pharmaceuticals For: Mar 31 | SEC filing · Form 10-Q | +0.63% | +0.55% | |
| Form 10-K Xenon Pharmaceuticals For: Dec 31 | SEC filing · Form 10-K | +1.29% | -3.59% | |
| Form 10-Q Xenon Pharmaceuticals For: Sep 30 | SEC filing · Form 10-Q | -1.42% | -1.64% | |
| Xenon Reports Third Quarter 2025 Financial Results & Business Update | Press release | -1.42% | -1.64% | |
| Form 10-Q Xenon Pharmaceuticals For: Jun 30 | SEC filing · Form 10-Q | +1.06% | — | |
| Xenon Reports Second Quarter 2025 Financial Results & Business Update | Press release | +1.06% | — | |
| Form 10-Q Xenon Pharmaceuticals For: Mar 31 | SEC filing · Form 10-Q | -6.75% | -9.78% | |
| Xenon Reports First Quarter 2025 Financial Results and Provides Business Update | Press release | -6.75% | -9.78% | |
| Form 10-K Xenon Pharmaceuticals For: Dec 31 | SEC filing · Form 10-K | -9.54% | +0.05% | |
| Form 10-Q Xenon Pharmaceuticals For: Sep 30 | SEC filing · Form 10-Q | +1.21% | -2.58% | |
| Form 10-Q Xenon Pharmaceuticals For: Jun 30 | SEC filing · Form 10-Q | +5.63% | +7.53% | |
| Form 10-Q Xenon Pharmaceuticals For: Mar 31 | SEC filing · Form 10-Q | -2.75% | -0.54% | |
| Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update | Press release | -2.75% | -0.54% | |
| Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Corporate Update | Press release | +0.00% | +0.39% | |
| Form 10-K Xenon Pharmaceuticals For: Dec 31 | SEC filing · Form 10-K | -0.09% | -5.75% | |
| Form 10-Q Xenon Pharmaceuticals For: Sep 30 | SEC filing · Form 10-Q | -2.12% | -10.23% | |
| Xenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update | Press release | -2.12% | -10.23% | |
| Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Corporate Update | Press release | +0.82% | +4.82% |
Keep exploring
More XENE: analyst actions → · SEC filings → · XENE overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| AtriCure, Inc. (ATRC) | 276 | +0.04% | 51% |
| Coherus Oncology, Inc. (CHRS) | 276 | +0.21% | 51% |
| Aclaris Therapeutics, Inc. (ACRS) | 275 | 0.00% | 48% |
| Anika Therapeutics Inc. (ANIK) | 275 | +0.07% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.